Redose
Most of the weight comes back. That's the plain finding from the two biggest withdrawal studies run so far, one on semaglutide and one on tirzepatide, and it's the part of the story that rarely makes it into a prescription conversation. So can you stop taking Ozempic? Physically, yes, and nothing in the trials suggests people are locked in, but the numbers after stopping are sobering.
A year after semaglutide 2.4 mg ended in the STEP 1 extension, participants had regained about two-thirds of what they'd lost. In SURMOUNT-4, people switched from tirzepatide to placebo put back 14% of their body weight over 52 weeks. Anyone asking can you stop taking Ozempic is really asking what happens next, and those trials are the best answer we've got. None of this is advice to stay on or come off a medication; that's a decision for you and your prescriber.
Can you stop taking Ozempic without losing the results?
The honest answer from the data is: usually not all of them. The trials don't show a cliff on day one. They show a slow climb that starts within weeks and keeps going for most of the following year. Appetite tends to return first, and the scale follows.
It also helps to separate the brands. Ozempic is approved for type 2 diabetes, while Wegovy is the same molecule at up to 2.4 mg approved for weight management, so the withdrawal trials below used the Wegovy dose. People using semaglutide for weight loss at lower Ozempic doses weren't studied in exactly this way, which matters when you compare your own numbers to the averages.
One year after withdrawal of semaglutide 2.4 mg and lifestyle intervention, STEP 1 participants regained two-thirds of their prior weight loss, and their cardiometabolic markers moved back with it.
What the STEP 1 extension found after semaglutide ended
STEP 1 gave adults without diabetes weekly semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group lost 17.3% of body weight on average, against 2.0% on placebo. A subset was then followed for another 52 weeks with no drug and no structured lifestyle program, and the results were published as the STEP 1 trial extension.
| Timepoint | Semaglutide arm | Placebo arm |
|---|---|---|
| Week 0 to 68, on treatment | 17.3% lost | 2.0% lost |
| Week 68 to 120, off treatment | 11.6 points regained | 1.9 points regained |
| Net change at week 120 | 5.6% below start | 0.1% below start |
| Kept 5% or more off at week 120 | 48.2% of people | 22.6% of people |
Two readings of that table are both true. Most of the loss was regained, and the semaglutide group still ended up lighter than where it began, with nearly half keeping at least 5% off. The authors concluded the findings confirm obesity is chronic and suggest ongoing treatment is needed to hold the improvements.
- Dose escalation ran 16 weeks, from 0.25 mg up to 2.4 mg weekly
- Structured lifestyle support ended at week 68 along with the drug
- Regain was steepest in the first months after the last injection
- Net loss at week 120 averaged 5.6%, not the 17.3% seen at week 68
Stopping tirzepatide in SURMOUNT-4 followed the same curve
SURMOUNT-4 was built to answer this exact question for tirzepatide. Everyone took open-label tirzepatide for 36 weeks at their maximum tolerated dose of 10 mg or 15 mg, losing 20.9% on average. Then 670 people were randomized to keep going or switch to placebo for 52 weeks, as reported in the SURMOUNT-4 paper in JAMA.
How big the gap got by week 88
The placebo group regained 14.0% of body weight between weeks 36 and 88, while those still on tirzepatide lost another 5.5%. Total loss from the start was 25.3% for people who stayed on the drug and 9.9% for those who stopped. Nearly 9 in 10 on continued tirzepatide kept at least 80% of their lead-in loss; only 16.6% of the placebo group did.
Why stopping tirzepatide for weight loss isn't a clean reset
The placebo arm didn't bounce all the way back to baseline within a year. People who are stopping tirzepatide for weight loss reasons, or because of cost or side effects, can look at that 9.9% figure as the average floor seen in this trial, not a guarantee. Individual results in both arms spread widely around those means.
In SURMOUNT-4, continuing tirzepatide produced a 25.3% total loss by week 88, while switching to placebo left people at 9.9%.
What happens when you stop Wegovy after a short course
STEP 4 tested a shorter run. Participants took semaglutide 2.4 mg for 20 weeks, losing 10.6%, then were split between continuing and switching to placebo for 48 weeks. Everyone kept getting monthly lifestyle counseling, a 500 kcal per day deficit target and 150 minutes of weekly activity.
Even with that support, the placebo group regained 6.9% while the continuing group lost a further 7.9%. By week 68 the totals were 17.4% for continued Wegovy for weight loss versus 5.0% for those switched early. Counseling alone didn't hold the line, which is useful context for anyone thinking of the drug as a short kick-start.
Blood pressure, HbA1c and lipids drift back too
Weight isn't the only thing that moves. In the STEP 1 extension, systolic blood pressure rose back toward baseline after withdrawal, and HbA1c increased in both arms. CRP and lipids climbed in the semaglutide arm too, though several stayed better than placebo at week 120.
For people using Ozempic for diabetes, that HbA1c drift is the number to watch most closely, because glucose control is the reason the drug was prescribed. Any plan to pause or change a GLP-1 is worth talking through with the prescriber first, including what glucose monitoring should look like afterward.
- Systolic blood pressure moved back toward baseline after stopping
- HbA1c rose in both arms during the off-treatment year
- CRP and lipids rose but partly stayed better than placebo
- Waist size tends to follow body weight in the same direction
What stopping GLP-1 treatment means in money and outcomes
Here's where the trial math meets a bank account. Through NovoCare Pharmacy self-pay pricing, Wegovy at 1 mg, 1.7 mg or 2.4 mg costs $349 a month after the introductory fills, and Ozempic 2 mg is $499. That makes a year of Wegovy roughly $4,188 at self-pay prices, before any insurance or savings card changes the picture.
| Scenario | Average net loss | Trial source |
|---|---|---|
| Semaglutide 68 weeks, then stop | 5.6% at week 120 | STEP 1 extension |
| Semaglutide 20 weeks, then stop | 5.0% at week 68 | STEP 4 |
| Semaglutide continued to week 68 | 17.4% at week 68 | STEP 4 |
| Tirzepatide 36 weeks, then stop | 9.9% at week 88 | SURMOUNT-4 |
| Tirzepatide continued to week 88 | 25.3% at week 88 | SURMOUNT-4 |
Put simply, a person weighing 100 kg who matched the STEP 1 averages would drop about 17 kg on semaglutide and sit roughly 6 kg below their start a year after stopping. That's still something, and for some people the health gains during treatment were the goal. But it's a very different return than the week 68 number, and the cost of the months already spent doesn't come back.
A year of self-pay Wegovy at $349 a month is about $4,188. Trial averages suggest most of what that year bought fades within a year of stopping.
Planning and tracking the conversation with your prescriber
The most common search on this topic is some version of how to not gain weight after stopping Ozempic. The trials above didn't test a proven off-ramp; STEP 4 kept counseling going and still saw regain. Some people and clinicians discuss protein, strength training and appetite strategies, which we covered in our guide to protein and lifting on GLP-1s and why food noise comes back.
What you can control is the record you bring to that appointment. Redose is for tracking and record-keeping only, but a clean log of doses, weight, side effects and appetite makes it far easier for a prescriber to judge whether any change is working. If you use compounded vials, the dose calculators keep the unit math consistent across a change.
- Log weight weekly at the same time and on the same scale
- Note appetite and food noise changes in the first 4 to 8 weeks
- Record any HbA1c, glucose or blood pressure readings you get
- Keep the exact last dose, date and injection site on file
Questions people ask about stopping GLP-1 medications
Do you have to stay on Ozempic forever?
No trial has settled that for every person. The STEP 1 extension authors wrote that their findings suggest ongoing treatment is required to maintain the improvements, and SURMOUNT-4 pointed the same way for tirzepatide. Whether that applies to you, including a lower maintenance dose, is a question for your prescriber, and our look at the week 60 plateau covers what the long-run curve looks like on treatment.
Are there semaglutide withdrawal symptoms?
The STEP trials didn't describe a withdrawal syndrome of the kind seen with some other drug classes. What they measured was weight, blood pressure, HbA1c and lipids moving back toward where they started. Many people report hunger returning within weeks, which fits the drug's effect on appetite wearing off as levels fall.
What happens when you stop Wegovy and restart it later?
Restarting after a long break usually means going back through the titration steps rather than jumping to the old dose, because nausea risk is highest when the body isn't used to the drug. The label covers how long a gap is too long. See our explainer on missed doses, and confirm the plan with whoever prescribes it.
Is semaglutide weight loss medication meant to be short term?
Wegovy weight loss medication was studied as a long-term treatment alongside diet and activity, and the withdrawal trials are the main reason clinicians frame it that way. Stopping GLP-1 therapy is still common, often for cost, supply or side effects, and the averages above are what the research says to expect.
Whatever you and your prescriber decide, keep a record of every dose with confidence. Download Redose for exact syringe units from the calculator, gentle reminders, injection site rotation, and a complete private log of your protocol and weight trend. Get the app here: iOS.